



Florida Cancer Innovation Fund Funding Opportunity Announcement (FOA)

Fiscal Year (FY) 2025-26

Released: September 24, 2025

Amended: October 3, 2025

Direct all questions about the online application process and related issues to:

Florida Department of Health
Division of Public Health Statistics and Performance Management
4052 Bald Cypress Way Bin A24, Tallahassee, Florida 32399-1725

Office: 850-245-4585

Email: FloridaCancerInnovationFund@flhealth.gov

Website: [Florida Cancer Innovation Fund | Florida Department of Health \(floridahealth.gov\)](https://cancerinnovation.floridahealth.gov/)

Application Portal: <https://cancerinnovation.floridahealth.gov/>

Table of Contents

1.	FOA KEY POINTS	3
2.	INTRODUCTION AND PROGRAM AUTHORITY.....	4
2.1.	The Casey DeSantis Cancer Research Program Mission	4
2.2.	Florida Cancer Innovation Fund	4
3.	HIGH-IMPACT EXPECTATIONS	4
4.	RESEARCH FOCUS.....	5
4.1.	Core Principles	5
5.	RESEARCH PRIORITIES	6
6.	GRANT CATEGORIES	7
7.	REQUIRED SUCCESS METRICS	8
8.	ELIGIBILITY	8
8.1.	Additional Requirements	9
9.	FUNDING INFORMATION	10
9.1.	Deadlines and Award Timeline	10
10.	REQUIRED GRANT APPLICATION COMPONENTS.....	11
10.1.	Application Process	12
11.	BUDGET	13
12.	EVALUATION CRITERIA	13
13.	POST-APPLICATION SUBMISSION	14
13.1.	Changes to a Submitted Application	14
13.2.	Evaluation of Applications	14
13.3.	Administrative Review.....	14
13.4.	Notification of Funding Decision.....	15
13.5.	Requests for Re-Consideration.....	15
14.	GRANTEE REQUIREMENTS.....	15
14.1.	Terms and Conditions.....	15
14.2.	Grantee Reporting Requirements	15
14.3.	Open Innovation and Sharing of Publication Related Materials, Data, and Software.....	15
15.	PROGRESS REPORTS	16
15.1.	Sample Agreement and Budget Summary	16

Information and Instructions for applying to the Florida Cancer Innovation Fund

1. FOA KEY POINTS

Applicants should note the following key points:

1. **High-Impact Focus:** This Funding Opportunity Announcement (FOA) supports one-year projects only that deliver immediate, measurable impact on cancer research, treatment, or patient care in Florida. Projects must demonstrate clear pathways to rapid clinical translation, commercialization, or implementation.
2. **Accelerated Timeline:** All funded projects must be completed within exactly 12 months. Projects requiring longer timelines or multi-year phases will not be considered.
3. **Return on Investment Requirements:** Applications must include specific, quantifiable deliverables and success metrics that demonstrate high return on Florida's investment, including but not limited to, publications, follow-on funding secured, clinical implementations, patient outcomes improved, or technologies advanced toward commercialization.
4. **Innovation Priority:** Projects must represent significant innovation beyond incremental advances. Priority will be given to breakthrough approaches, novel technologies, or transformative treatment models with immediate applicability especially in prioritized research areas.
5. **Principal Investigator Requirements:** Applicants must identify only one Corresponding Principal Investigator, herein named the Principal Investigator (PI), for each application. Refer to the Eligibility section of this FOA for more information about the PI.
 - Co-Principal Investigators (Co-PIs) are allowed under this FOA, though there must be only one PI listed for each grant project. Co-PIs are optional and serve as secondary PIs on the project. Refer to the Eligibility section of this FOA for more information about PIs and Co-PIs.
6. **Single Application Rule:** Each applicant may submit only one application per funding cycle. An application may not be submitted in more than one grant category.
7. **Rolling Application Process:** Applications will be accepted during three rolling periods throughout Fiscal Year (FY) 2025-26. Applications open September 29, 2025, with deadlines on October 27, November 25, and January 9, 2026. Each Principal Investigator may submit only one application per fiscal year. Applications not funded in earlier periods will automatically be considered in subsequent periods.
8. **Total Funding:** A total of approximately \$60 million is available for all research grants funded through this FOA. Funding for this program is subject to the annual appropriation of funds by the Florida Legislature and granted spending authority to the Florida Department of Health (Department).
9. **New Priority Categories:** This year introduces dedicated funding categories for nutrition-based cancer prevention research and generic drug repurposing research (e.g., Ivermectin), reflecting Florida's leadership in comprehensive cancer prevention and accessible treatment innovation.

2. INTRODUCTION AND PROGRAM AUTHORITY

2.1. The Casey DeSantis Cancer Research Program Mission

The Casey DeSantis Cancer Research Program is established to enhance the quality and competitiveness of cancer care in this state, further a statewide biomedical research strategy directly responsive to the health needs of Florida's citizens, capitalize on the potential educational opportunities available to its students, and promote the provision of high-quality, innovative health care for persons undergoing cancer treatment in this state.

Under s. 381.915(9), Florida Statutes, the legislature has established the Florida Cancer Innovation Fund under the Casey DeSantis Cancer Research Program to support innovative cancer research and treatment models, including emerging research and treatment trends and promising treatments that may serve as catalysts for further research and treatments.

2.2. Florida Cancer Innovation Fund

During FY 2025-26, there is \$60 million available for all research grants funded through the Florida Cancer Innovation Fund. Funding for this FOA is subject to the annual appropriation of funds by the Florida Legislature and granted spending authority to the Department.

This year's FOA represents an expanded commitment to comprehensive cancer prevention and treatment innovation, including dedicated support for clinical trials, nutrition-based prevention research, and generic drug repurposing initiatives.

Through this FOA, the Florida Department of Health is accepting applications for innovative cancer research and treatment models. The purpose of this effort is to energize collaborations between oncologists, cutting-edge researchers, and cancer facilities and to provide a plausible route for expedited funding to bolster competitiveness for extramural cancer research funding.

This funding aims to provide opportunities to break down longstanding silos between researchers, cancer facilities, and medical providers to improve cancer research and treatment through rapid innovative approaches to cancer research.

Funding is for Florida-based institutions only.

3. HIGH-IMPACT EXPECTATIONS

All funded projects must demonstrate potential for immediate, transformative impact on cancer care in Florida through one or more of the following pathways:

Immediate Clinical Translation	Direct implementation in clinical practice within 12 months. Completion of clinical trials with actionable results. Development of clinical protocols ready for broad adoption.
Rapid Research Advancement	Completion of proof-of-concept studies leading to larger trials. Production of intellectual property ready for licensing or commercialization.

Healthcare Delivery Innovation	Implementation of new care delivery models with measured patient outcomes. Development of cost-effective treatment protocols with demonstrated savings. Creation of scalable interventions ready for statewide deployment.
Prevention and Accessibility Innovation	Development of evidence-based nutrition protocols for cancer prevention. Validation of generic drug repurposing for improved treatment accessibility. Creation of cost-effective prevention or treatment models.

4. RESEARCH FOCUS

The Casey DeSantis Research Program was established to fund high-impact innovative cancer research and treatment, which are increasingly shaped by short-term, innovative projects that deliver measurable returns.

During FY 2025-26, the Florida Cancer Innovation Fund will concentrate on one-year, high-impact initiatives with a focus on foundational discoveries, early-stage diagnostics, or scalable technologies that can rapidly influence clinical practice. Funded projects will be agile, interdisciplinary, and outcome driven, prioritizing translational potential.

By emphasizing short-cycle innovation and strategic funding, the Florida Cancer Innovation Fund will accelerate progress toward more personalized, accessible, and cost-effective care, while delivering strong economic and societal value.

The Florida Cancer Innovation Fund prioritizes rapid-cycle innovation that delivers immediate, measurable improvements to cancer care in Florida. Unlike traditional multi-year research grants, funding under this FOA supports projects designed to achieve breakthrough results within 12 months.

4.1. Core Principles

- Projects must show clear pathways to immediate clinical, research, or policy impact.
- Results must be scalable and applicable beyond single institutions to benefit Florida statewide.
- Projects should focus on breakthrough approaches rather than incremental improvements.
- Project should translate and emphasize on moving discoveries from bench to bedside within the grant period.
- If applicable, projects should have a prevention-first approach, with priority for projects addressing root causes of cancer through nutrition, lifestyle, and accessible treatment options.
- Projects should also place an emphasis on solutions that improve treatment access and affordability.
- Projects should have all regulatory approvals in place before commencement.

Each project should have clear end points with specific, measurable outcomes achievable within 12 months and could adapt to approaches based on early results. Further, projects should be collaborative ready and ensure that immediate collaboration with other researchers or institutions at the start of the project.

By concentrating on high-velocity, outcome-driven projects, the Florida Cancer Innovation Fund accelerates progress toward more personalized, accessible, and cost-effective cancer care while delivering exceptional return on Florida's investment in cancer research.

5. RESEARCH PRIORITIES

When responding to this FOA, applicants should consider the following types of research:

- **Translational Research:** Projects designed to translate scientific bench discoveries to practical therapeutic interventions in a clinical setting within 12 months. These efforts must relate to studies ready for immediate translation to human subjects or translation to clinical practice with measurable patient outcomes.
- **Implementation Research:** Research projects focused on methodologies designed to promote the rapid implementation of verified clinical treatments and practices into routine healthcare protocols. These studies must demonstrate measurable improvements in patient care within the 12-month grant period.
- **Clinical Trials:** Rigorously designed research studies that can be completed within 12 months and evaluate novel approaches for the prevention, diagnosis, and treatment of cancer in human subjects. Priority given to trials that can generate actionable results for immediate clinical application.
- **Direct Interventions:** Systematic testing of specific actions such as therapies, programs, or policies applied directly to individuals or populations to produce measurable health outcomes within 12 months. Projects must demonstrate clear causal relationships and immediate effectiveness.
- **Nonmetropolitan/Medically Underserved Areas:** Research that expands cancer screening efforts and innovative treatment models into underserved areas of Florida. Priority will be given to applications that demonstrate immediate impact on healthcare access and outcomes in these communities.
- **Technology Transfer Feasibility (TTF):** Projects that assess the successful transfer of technologies from research settings to practical applications within 12 months. Focus on developing intellectual property and enhancing commercial potential through activities that demonstrate technical merit, feasibility, and market competitiveness.
- **Novel Treatments:** Development and testing of novel cancer treatments, cost-effective generic drugs, and supportive holistic therapies that can show measurable patient impact within the grant period. Projects must demonstrate immediate clinical applicability and potential for broad adoption.
- **Nutrition-Based Cancer Prevention Research:** Research focused on food-based interventions, dietary patterns, bioactive compounds, and precision nutrition approaches for cancer prevention. Projects must demonstrate measurable prevention outcomes within 12 months and potential for community-wide implementation.
- **Generic Drug Repurposing Research:** Studies investigating the repurposing of existing FDA-approved medications for cancer treatment applications. Projects must focus on drugs with established safety profiles and demonstrate potential for rapid clinical translation and improved treatment accessibility. Studies must demonstrate that they can be completed and

show measurable outcomes within 12 months.

6. GRANT CATEGORIES

Applications will be accepted in the following categories, each designed for maximum impact within 12 months. An application may not be submitted in more than one grant category.

1. **Rapid Translation Grant:** This grant category supports fast-track promising laboratory discoveries to clinical application. Grants in this category must demonstrate that preclinical work is ready for clinical translation, that regulatory approvals have been obtained before commencement, included a clinical implementation plan within 12 months, and have a health care partner ready to commit to adoption.
2. **Consortium Grant:** This grant category supports a consortium of clinical, basic, translational, and underrepresented research institutions across Florida to conduct high-quality, grant-funded research. The award will be made to a lead organization, which must play a central role in executing the research plan and overseeing all scientific, programmatic, financial, and administrative aspects. Collaborating institutions must have clearly defined responsibilities that advance shared research goals, supported by strong background rationale, testable hypotheses, robust protocols, and validated best practices addressing one or more priority areas.
3. **Clinical Trials:** These grants directly support the planning, execution, and assessment of studies with well-defined protocols, ethical compliance, and precise data collection to generate evidence for clinical practice and regulatory decisions. Funding may cover early-phase safety studies, efficacy trials, or large-scale effectiveness research, with the goal of generating high-quality evidence to inform clinical practice, regulatory approval, and public health policies.
4. **High Impact Pilot Grant:** A high-impact pilot grant in cancer research provides early-stage funding for bold, innovative projects that have the potential to transform cancer prevention, diagnosis, or treatment. These grants support the development of novel ideas, technologies, or approaches by enabling researchers to generate preliminary data, test feasibility, and refine hypotheses. Focused on scientific merit and breakthrough potential, cancer pilot grants serve as a launchpad for larger-scale studies and accelerate progress toward meaningful clinical advances that improve patient outcomes.
5. **Integrated Cancer Care Innovations:** This grant category supports research and development efforts focused on advancing novel cancer therapies, increasing access to cost-effective generic treatments, and integrating holistic approaches that promote patient-centered care. Proposed projects should emphasize scientific innovation, affordability, and whole person health, contributing to improved clinical outcomes and patient well-being.
6. **Nutrition and Food-Based Cancer Prevention Grant:** These grants are available to develop and validate nutrition-based cancer prevention strategies with a focus on whole foods, dietary patterns, or bioactive compounds. Grants must have measurable prevention outcomes within 12 months, have community-based implementation potential, have alignment with precision nutrition and Florida MAHA principles, and have evidence of safety and efficacy for all populations.
7. **Generic Drug Repurposing Grant:** These grants are focuses specifically on the repurposing of existing FDA-approved medications for cancer treatment. Grants may focus on drugs with established safety profiles, have a clear rationale for anti-cancer efficacy, have feasible clinical trial design completable within 12 months, have the potential for immediate clinical translation upon success, and show demonstrated cost-effectiveness compared to current treatments.

7. REQUIRED SUCCESS METRICS

Applications must specify quantifiable outcomes such as those listed in the following categories.

Publications	Number of peer-reviewed publications submitted within grant period.
Follow-on Funding	Total number of applications for federal or private funding.
Clinical Implementation	Number of patients or facilities impacted by project outcomes.
Economic Impact	Return on investment identified and identified cost savings.
Commercialization	Patents filed, licenses executed, or partnerships established.
Workforce Development	Number of researchers, clinicians, or students trained.
Policy Influence	Recommendations and best practices adopted by healthcare systems or regulatory bodies.
Prevention Impact	Measurable improvements in cancer risk reduction or early detection.
Accessibility Improvements	Increased access to effective treatments through cost reduction or availability.
Collaboration	Number of new partners formalized.
Information Dissemination	Number of best practices, protocols or data disseminated to the public.

8. ELIGIBILITY

Grant applications failing to meet all eligibility requirements will be rejected.

To be eligible for grant funding under the Florida Cancer Innovation Fund, a licensed or certified health care provider, facility, or entity must meet at least one of the following criteria as specified in Florida Statute 381.915(9)(b):

1. **Operates as a licensed hospital** that has a minimum of 30 percent of its current cancer patients residing in rural or underserved areas.
2. **Operates as a licensed health care clinic or facility** that employs or contracts with at least one physician licensed under chapter 458 or chapter 459 who is board certified in oncology and that administers chemotherapy treatments for cancer.
3. **Operates as a licensed facility** that employs or contracts with at least one physician licensed under chapter 458 or chapter 459 who is board certified in oncology and that administers radiation therapy treatments for cancer.
4. **Operates as a licensed health care clinic or facility** that provides cancer screening services at no cost or a minimal cost to patients.

5. **Operates as a rural hospital** as defined in s. 395.602(2)(b).
6. **Operates as a critical access hospital** as defined in s. 408.07(14).
7. **Operates as a specialty hospital** as defined in s. 395.002(28)(a) which provides cancer treatment for patients from birth to 18 years of age.
8. **Operates as a licensed hospital** that is accredited by the American College of Surgeons as a Comprehensive Community Cancer Program or Integrated Network Cancer Program.
9. **Engages in biomedical research** intended to develop therapies, medical pharmaceuticals, treatment protocols, or medical procedures intended to cure cancer or improve the quality of life of cancer patients.
10. **Educates or trains students, postdoctoral fellows, or licensed or certified health care practitioners** in the screening, diagnosis, or treatment of cancer.

8.1. Additional Requirements

1. Collaborations are acceptable and encouraged. However, all grant-funded activities must take place in Florida. All work (effort) must occur, and funds must be spent in Florida at the applicant organization and any collaborating entities. The Department may make exceptions if the service is essential and only provided outside Florida, and if the amount is less than 10 percent of the requested amount.
2. Subcontracts must be pre-approved in the Public Health Research Program Budget Template. The Budget Narrative must justify the purpose of the subcontract, whether this is the only vendor that can perform the services, regardless of if they are in-state or out-of-state.
3. Each project proposal must identify a Corresponding Principal Investigator (PI). The PI is the individual, designated by the Applicant, who is legally responsible to direct the project and is accountable for the project's scientific and technical direction as well as the proper conduct of the project. There may be multiple PIs (called Co-PIs) on a project, but there must be only one designated PI.
 - a. The PI must be an employee of the applicant organization/entity and meet that institution's criteria for serving as a PI in addition to meeting the eligibility requirements listed in this FOA.
 - b. The PI must be a U.S. citizen or permanent resident; unauthorized aliens shall not be employed pursuant to §274A(e) of the Immigration and Naturalization Act (8 U.S.C. 1324a), section 101 of the Immigration Reform and Control Act of 1986, and Florida Executive Order 11-02. Non-U.S. citizens can serve as Collaborators or members of a research team.
 - c. The PI may serve as Co-PI or other role on other applications, provided they are not over-committed. The Corresponding Principal Investigator shall not:
 - Apply for the same research project for which he or she was a previously funded grant recipient
 - Submit the same project/research that is also being submitted by another investigator regardless of the grant mechanism

- Submit duplicate projects or projects with significant scientific or financial overlap during the same competition year
- 4. Applicants must ensure that their proposed project does not duplicate or significantly overlap, scientifically or financially, with other projects in which they or any key personnel are involved.
- 5. Applicants must report whether the applicant organization, the PI, or other individuals who contribute to the execution of the proposed grant are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date.
- 6. Florida Cancer Innovation grants will be awarded by contract to successful applicants.
- 7. Before the Department will issue the grant for execution, the grantee must submit regulatory approvals including Institutional Review Board determinations and study approvals, data use agreements, and study protocols to the Department.

9. FUNDING INFORMATION

Applicants may request up to \$2 million in research funding under this FOA. Award allocations are based on the scope of the project and dependent on funds available, subject to the annual appropriation of funds by the Florida Legislature and spending authority granted to the Department. All direct costs must be specifically and directly related and allocated to the project, necessary for the project's completion, adequately justified, and made during the active grant period. Any other costs are disallowed. See the Budget Guidelines section for details.

9.1. Deadlines and Award Timeline

1. The application process will be as follows:
 - a. The FOA release date is September 24, 2025.
 - b. A pre-application period which begins when the FOA is released and ends when the application portal opens.
 - c. The initial application period for Florida fiscal year July 1, 2025-June 30, 2026, begins on September 29, 2025, and will remain open until January 9, 2026.
 - d. There will be three grant award periods.
2. A pre-application webinar will be held on October 1, 2025. During this time any questions will be solicited, and answers will be posted two business days after the Q&A deadline, which is October 3, 2025.
 - a. Between September 25, 2025, and October 1, 2025, the Department will solicit any questions pertaining to the FOA.
 - b. After October 1, 2025, the Department will be unable to answer any questions until the application period has closed.
 - c. The Department will respond to questions received, and post on its website on October 3, 2025.
3. The application period will be on a rolling basis during Florida fiscal year 2025-2026:
 - a. **Period 1:** Applications open September 29, 2025, and will be closed for review on October 27, 2025. Any applications not received by 11:59 P.M. on October 27, 2025, will be eligible for review in Period 2.

- b. **Period 2:** Applications re-open October 28, 2025, and will be closed for review on November 25, 2025. Any applications not received by 11:59 P.M. on November 25, 2025, will be eligible for review in Period 3.
- c. **Period 3:** Applications re-open November 26, 2025, and will be closed for review on January 9, 2026.
- d. Applications received after 11:59 PM on January 9, 2026, will not be reviewed.
- e. Applications received during application period one and two will also be considered against other applications received during application period three if not funded in the previous application period that they were submitted under.
- f. Applicants will be notified following Cancer Connect Collaborative review; review and notification dates are subject to change.

10. REQUIRED GRANT APPLICATION COMPONENTS

A complete grant application package must contain all required items listed in the below table.

Category	Comment
General Audience Abstract	Required. Identifies general project information, the applicant organization, and the Corresponding Principal Investigator.
Scientific Abstract	Required. This is the scientific description of the project. Applicants will complete this in the General Project Information section of the application.
Project Collaborators	Required. A list of collaborators, the institution/facility, department, brief description of role in project (Scientific mentor, Coinvestigator, etc.)
Specific Aims	Required. State the goals of the proposed research and summarize the expected outcomes.
Research Strategy	Required. State the goals of the proposed research and summarize the expected outcomes, including the impact that the results of the proposed research will exert on the field involved.
Long-term Goals	Required. Describe the future direction of the research, long-term goals, and the project timeline for submitting additional grant application(s) to other federal or state funding

	opportunities. Explain the benefits/Return on Investment (ROI) to the state of Florida.
Budget	Required: Complete a 12-month line-item budget as well as providing a budget narrative justifying each item. Budgets should be organized to cover personnel, equipment, supplies, and technical support.
Professional Qualifications/Experience	Required. Please submit a curriculum vitae, resume or bio sketch.
Letters of Support	Required. A letter of support is a document designed to corroborate the proposed research through a third-party. Letter of Support from the Resource officer. The document should provide testimony that supports the anticipated study and methods.
Work and Evaluation Plan	Required. Must complete a 12-month work and evaluation plan with measurable outcomes.
Regulatory Approvals	Required (if applicable). Describe protections for human subjects, animals, embryonic stems cells and/or recombinant DNA involved in the research. If human subjects will be involved at any time in the research, even if the project protocol has already received Institutional Review Board approval or is deemed exempt, the applicant must address all human subject questions in the online application. If all questions are not answered, the application will be disqualified. Must have regulatory approvals in place before project commencement and contract execution.

10.1. Application Process

To complete the online application process:

1. Go to the program website at <https://cancerinnovation.floridahealth.gov/> and complete all fields to register. You will receive an email with details about the next steps.
2. Access the online application and other required forms and submit them along with any necessary attachments using the same website link (<https://cancerinnovation.floridahealth.gov/>) between September 29, 2026 , at 10:00 a.m. Eastern Time (ET), and January 9, 2026, at 11:59 p.m. ET. Application submissions will be followed with an email indicating acceptance of the application and next steps, or denial of the same and reasons why. PDF versions of the online application and related required forms will be posted in the Florida Cancer Innovation Fund Announcement webpage when available. ([Florida Cancer Innovation Fund | Florida Department of Health \(floridahealth.gov\)](#)).

3. If you experience technical problems with the website, please call 850-245-4744, Monday through Friday, between 8:00 a.m. and 6:00 p.m. ET).
4. For questions about the funding opportunity, email FloridaCancerInnovationFund@flhealth.gov.

11. BUDGET

Awards can be up to \$2,000,000 each. Award allocations will be based on scope of the project and dependent on funds available. Budgets should be structured to include personnel, equipment, supplies, and technical support. Budgets need to include a justification for each item, personnel (names and position), and percentage of effort devoted to the project percentage. Any equipment purchases that exceed \$5,000 are subject to further review and approval by the department.

11.1. Disallowed Costs

All direct costs must be specifically and directly related and allocated to the project, necessary for the project's completion, adequately justified, and made during the active grant period. Any other costs are disallowed. Additionally, the following items shall NOT be paid for with grant funds:

- Florida Department of Health personnel salary
- Construction, renovation, or remodeling
- International travel (including Canada)
- Vehicles
- Entertainment
- Employment subsidies
- Dues/Membership fees
- Lobbying
- Meals/Food (other than as part of travel costs)
- Malpractice insurance premiums
- Expenditures related to legal services, business filing fees, or other costs for visas, green card or similar processing fees.

12. EVALUATION CRITERIA

Evaluations will be based on scientific merit, 12-month feasibility, ability to start the project on day one of contract execution (e.g., regulatory approvals and/or partnerships are all on hand), potential to extract funding from extramural sources and capacity to stimulate innovation pertaining to cancer research and care in Florida. Specific evaluation criteria will focus on:

1. Innovation and significance to cancer research and care with a priority given to projects that streamline patient trials to clinical practice.
2. Priority will be given to new applicants who have not previously received funding from either the cancer innovation fund or from other state-funded cancer research programs administered by the Department of Health.
3. Additional merit and priority will be awarded to those concentrating on research or treatment within rural or underserved populations, and studies or interventions targeting modifiable risk factors such as diet and nutrition or other evidence-based non-pharmaceutical interventions related to cancer prevention and treatment.

4. Additional merit will also be awarded to research related to the use of generic drugs for cancer care and treatment.
5. Productivity, feasibility, and capacity to complete the proposed treatment or research:
 - **Productivity:** Assess the anticipated output and effectiveness of the treatment or research project, including the ability to achieve milestones and deliverables within the proposed timeline.
 - **Feasibility:** Evaluate the practicality of the project, considering factors such as resource availability, logistical considerations, and any potential obstacles that could impact the project's success.
 - **Capacity:** Determine the ability of the team or organization to successfully carry out the project, including assessing the expertise, experience, and resources available to ensure the completion of the proposed treatment or research.

13. POST-APPLICATION SUBMISSION

13.1. Changes to a Submitted Application

It is the responsibility of the applicant to ensure that a complete application is submitted before the date and time specified in Deadlines and Award Timelines. The Department does not allow submitted application files or data to be replaced or changed after the submission deadline. This decision will help ensure no applicants receive an unfair advantage. Before submitting your application, please check it for completeness, accuracy, quality, and readability. This should include verifying that all graphic elements, including tables, charts, and images are converted properly when saving the original documents in PDF format as required.

13.2. Evaluation of Applications

The Department will use a multi-step evaluation and review process before making award determinations for all applications submitted in response to this Funding Opportunity. The Cancer Connect Collaborative, herein after "Collaborative," shall advise the Department on the awarding of grants issued through FCIF. During any fiscal year for which funds are appropriated to FCIF, the collaborative shall review all submitted grant applications and make recommendations to the department for awarding grants. The Department will consider the outcome of each of these evaluation steps in making final funding recommendations to the State Surgeon General.

13.3. Administrative Review

Application materials not received according to the date, time, and location specified in Deadlines and Award Timelines will be disqualified. Each application submitted by the deadline indicated in Deadlines and Award Timelines will receive an administrative review verifying mandatory eligibility requirements, budget compliance, and the completeness of the application. The administrative review includes a check for potential scientific or budgetary overlap with active or pending projects supported by the Department. The administrative review does not include review of the overall scientific impact.

Any application failing to meet all administrative requirements may be ruled ineligible for funding in response to this FOA, not entitled to further consideration, and will not undergo peer review.

The Department reserves the right to disqualify all applications or to waive minor irregularities when doing so would be in the best interest of the State of Florida. A minor irregularity is defined as a variation from the specifications of this FOA that does not give any applicant an advantage or benefit not enjoyed by other applicants, does not affect the cost of the application, nor adversely affect the interests of the State of Florida. At its option, the Biomedical Research Program may correct minor irregularities but is under no obligation to do so.

13.4. Notification of Funding Decision

The applicant organization and PI will receive written notification via email of the funding decisions. All awards in response to this FOA are subject to the availability of funds and spending authority provided by the Florida Legislature. By submitting a grant application pursuant to this FOA, all applicants acknowledge and consent to this condition.

13.5. Requests for Reconsideration

All funding decisions of the State Surgeon General or designee are final.

14. GRANTEE REQUIREMENTS

14.1. Terms and Conditions

After awards are made, each grantee must sign a contract, called the "Terms and Conditions," agreeing to certain legal requirements of the award. The Terms and Conditions are non-negotiable, and acceptance are required as part of the grant award process. The Department reserves the right to change or modify the Terms and Conditions as needed. The Terms and Conditions include the post-award schedule of deliverables.

14.2. Grantee Reporting Requirements

If the applicant's proposal is funded, the Grantee must respond to Department requests for information for a period of five years after the end of the grant period, including any no cost extensions. The requested information may include but is not limited to long-term outcomes based on the funded project, including the value of additional grant awards for cancer research, a list of cancer presentations, a list of cancer publications in peer-reviewed journals, commercialization results and any invention disclosures, patent filings, and patents received.

14.3. Open Innovation and Sharing of Publication Related Materials, Data, and Software

Publishing a scientific paper is a transaction whereby the author(s) receive credit and status in exchange for sharing their scientific findings. Authors have a responsibility to make available materials, databases, and software integral to their findings so that others may validate or refute the results and/or extend them in new directions. Grantees funded through the Department are encouraged to use material transfer agreements to make materials, data and databases, and software that result from this funding and which is integral to their research findings, freely and promptly available upon request for research use by other scientists. Also, grantees should provide a copy of any article published from research supported by this Program to the Department within three months of the date the article is published.

In accord with the National Institutes of Health notice NOT-OD-08-033, Grantees shall submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication, in a manner consistent with copyright law. This applies to all publications resulting from the Department funded projects/research. For more information on the NIH Open Access Policy, visit <http://publicaccess.nih.gov/>.

15. PROGRESS REPORTS

Detailed quarterly summaries assessing progress will be required for all funded projects. These summaries will include performance updates, successes, and unexpected barriers. Final progress reports will be due at the end of the project cycle or annually depending upon the agreement and will outline the impact on cancer research and patient care that the proposal has had on Floridians living with cancer.

Typically, there is a reconciliation of funds that also results in the final payment.

15.1. Sample Agreement and Budget Summary

A copy of a sample Terms and Conditions and the Budget Summary are available on our website: <https://cancerinnovation.floridahealth.gov>. There will be a review period after the Awards are made to revise the Grant Budget Summary and Narrative. No modifications will be allowed once the Budget Revisions are complete, and the entire review packet is routing in our contract review system.

All awards in response to this funding opportunity are subject to the availability of funds and spending authority provided by the Florida Legislature. By submitting a grant application pursuant to this Funding Opportunity, all applicants acknowledge and consent to this condition.